We are extremely pleased to announce that the Sonablate High Intensity Focused Ultrasound (HIFU) has been approved by the FDA. HIFU has been used to treat over 65,000 men with prostate cancer around the world for several years. It can have the same effect as surgery or radiation, but with fewer side effects. HIFU is most effective for patients with early stage prostate cancer where the cancer is localized to the prostate. It is non-invasive and performed on an outpatient basis. If the HIFU procedure is performed in the morning, a patient can often return to normal activity within a few hours without the use of painkillers.
HIFU stands for “High Intensity Focused Ultrasound”, or sometimes MRgHIFU for magnetic resonance guided focused ultrasound. It is a medical procedure that applies high intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue through ablation. This accuracy allows the preservation of healthy tissue, nerves, and urine flow. As a result, erectile function is unharmed in about 80% of cases compared to 40%–50% with surgery or radiation.
It is one of very few therapies involving non-invasive methods of precision acoustic energy into the body. Treatment with HIFU waves use heat focused at a specific location to destroy the area of the prostate gland affected with cancer, while any tissue outside of the focal point remains unharmed. Given the nature of this nonsurgical outpatient treatment, published medical data has shown HIFU to treat prostate cancer with more accuracy while producing a much lower rate of side effects compared to radiation and radical (Robotic) surgery.